Inhaled iloprost: In primary pulmonary hypertension

Drugs

Volumn 64, Issue 7, 2004, Pages 763-773

  Goldsmith, David R ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; TOLAFENTRINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; JAW; LUNG GAS EXCHANGE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NAUSEA; PAIN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYNCOPE; VASCULAR RESISTANCE; VERTIGO;

ADMINISTRATION, INHALATION; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST;

EID: 1842739572     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464070-00009     Document Type: Review

References (37)

1. Pass SE, Dusing ML. Current and emerging therapy for primary pulmonary hypertension. Ann Pharmacother 2002 Sep; 36 (9): 1414-23
2. Gaine SP, Rubin LJ. Primary pulmonary hypertension [published erratum appears in Lancet 1999 Jan 2; 353: 74]. Lancet 1998 Aug 29; 352: 719-25
3. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003 May 3; 361: 1533-44
4. De Backer TLM, Smedema J-P, Carlier SG. Current management of primary pulmonary hypertension. Biodrugs 2001; 15 (12): 801-17
5. Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs 2001; 61 (13): 1945-56
6. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996 Feb 1; 334 (5): 296-301
7. Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992 Jun; 43 (6): 889-924
8. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002 Aug 1; 347 (5): 322-9
9. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002 Feb; 26 (2): 194-201
10. Wiedemann R, Ghofrani HA, Weissmann N, et al. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation. J Am Coll Cardiol 2001 Oct; 38 (4): 1130-6
11. Wilkens H, Bauer M, Forestier N, et al. Influence of inhaled iloprost on transpulmonary gradient of big endothelin in patients with pulmonary hypertension. Circulation 2003 Mar 25; 107 (11): 1509-13
12. Olschewski H, Rohde B, Behr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerolized by three different devices in severe pulmonary hypertension. Chest 2003 Oct; 124 (4): 1294-304
13. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension: German PPH study group. J Am Coll Cardiol 2000 Jan; 35 (1): 176-82
14. Galiè N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002 Oct; 20 (4): 1037-49
15. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. German PPH Study Group. Ann Intern Med 2000 Mar 21; 132 (6): 435-43
16. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000 Jun 22; 342 (25): 1866-70
17. Ewert R, Wensel R, Opitz CF. Aerosolized iloprost for primary pulmonary hypertension [letter]. N Engl J Med 2000 Nov 9; 343 (19): 1421-2
18. Opitz CF, Wensel R, Ewert R, et al. Preserved long-term efficacy of iloprost inhalation therapy over 2 years in patients with primary pulmonary hypertension [abstract no. 1113-52]. J Am Coll Cardiol 2000 Feb; 35 (2 Suppl. A): 286A
19. Behr J, Nikkho S, Borst M, et al. Long-term hemodynamic response in patients with pulmonary hypertension inhaling iloprost (AIR-2 study) [abstract no. 3535]. Eur Respir J 2003 Sep; 22 Suppl. 45: 562S
20. Wensel R, Opitz CF, Ewert R, et al. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 2000 May 23; 101 (20): 2388-92
21. Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest 2002 May; 121 (5): 1566-71
22. Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003 Feb; 24 (4): 356-65
23. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996 May 1; 124 (9): 820-4
24. 2) infusion for severe pulmonary hypertension (PH) [abstract no. P2836]. Eur Respir J 2000 Aug; 16 Suppl. 31: 395S
25. Petkov V, Ziesche R, Mosgoeller W, et al. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 2001 Sep; 56 (9): 734-6
26. Ghofrani HA, Rose F, Schermuly RT, et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002 Nov; 30 (11): 2489-92
27. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002 Apr 2; 136 (7): 515-22
28. Wilkens H, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001 Sep 11; 104 (11): 1218-22
29. Gessler T, Schmehl T, Rose F, et al. Co-application of oxygen improves iloprost inhalation in pulmonary hypertension patients with long-term oxygen therapy [abstract no. 2163]. Eur Respir J Suppl 2001 Sep; 18 Suppl. 33: 324S
30. Beghetti M, Reber G, de MP, et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 2002 Mar; 19 (3): 518-24
31. Schermuly RT, Schulz A, Ghofrani HA, et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J Pharmacol Exp Ther 2002 Nov; 303 (2): 741-5
32. The European Agency for the Evaluation of Medicinal Products. Ventavis®: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2004 Jan 28]
33. Nicolini FA, Mehta JL, Nicholds WW, et al. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. Circulation 1990 Mar; 81 (3): 1115-22
34. Kerins DM, Roy L, Kunitada S, et al. Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue [published erratum appears in Circulation 1992 Aug; 86 (2): 698]. Circulation 1992; 85 (2): 526-32
35. Penin E, Cheymol G, Bouslama K, et al. No pharmacokinetic interaction between iloprost and digoxin. Eur J Clin Pharmacol 1991; 41 (5): 505-6
36. Nikkho S, Seeger W, Baumgartner R, et al. One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension [abstract no. 2164]. Eur Respir J Suppl 2001 Sep; 18 Suppl. 33: 324S
37. Hoeper MM, Spiekerkoetter E, Westerkamp V, et al. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J 2002 Aug; 20 (2): 339-43